# 680 – 💊 How’d the drug shortage get so bad? – The Average Joe


Latest Issues Subscribe


About Us Jobs

Become a better investor with our free daily newsletters

Join 250,000+ investors discovering new market trends and ideas.

    # 680 – 💊 How’d the drug shortage get so bad?


    April 24, 2024

    .bh__table, .bh__table_header, .bh__table_cell { border: 1px solid #C0C0C0; }
    .bh__table_cell { padding: 5px; background-color: #FFFFFF; }
    .bh__table_cell p { color: #2D2D2D; font-family: ‘Helvetica’,Arial,sans-serif !important; overflow-wrap: break-word; }
    .bh__table_header { padding: 5px; background-color:#F1F1F1; }
    .bh__table_header p { color: #2A2A2A; font-family:’Trebuchet MS’,’Lucida Grande’,Tahoma,sans-serif !important; overflow-wrap: break-word; }

    Good morning. Nothing hurts your self-esteem like screwing up a Captcha. But don’t feel bad: they’re getting trickier. As bots become more sophisticated, we have to jump through hoops to prove we’re human — moving puzzle pieces, identifying obscure objects, and more. Worse, all these Captchas we’ve completed are helping Google train its machine learning database.

    So you might want to brush up on those logic puzzles — because Captchas will only get harder as the line between man and machine becomes fuzzier.


    The Bidding War That Could Change the Music Industry: Inside the Battle for Hipgnosis

    For decades, music labels were the only investors in the music industry — offering artists upfront cash in exchange for a share of their future earnings. But with legacy music businesses languishing, investment firms like Apollo ($APO) and BlackRock ($BLK) are pouring billions into buying stakes in artists’ catalogs, hoping to cash in on the music industry’s growth. However, not all investors are hitting the right notes.

    Hipgnosis no more: Take Hipgnosis Songs Fund ($HPGSF), the first publicly traded music investment company. They’ve splashed out nearly $2.2B to acquire over 57K music royalty rights. But with shares dropping 11% over the last five years to a record low and facing a slew of auditing and management controversies, shareholders finally voted for the company to be reorganized. Now, Hipgnosis is at the center of a bidding war among top music royalty investors.

    • Last week, Hipgnosis agreed to sell itself to the world’s largest music investor, Concord, for $1.4B — financed by Apollo Asset Management.

    • Days later, Apollo’s competitor Blackstone ($BX) also threw their hat in the ring with a $1.5B cash offer, capturing the attention of the fund’s board.

    Make music, not money

    Hipgnosis may have overestimated the value of their catalogs — expecting music royalties to rise in value. Except they didn’t expect 5%+ interest rates and inflation to take a bite out of the industry’s growth since 2020. Other investors might be more lucky. Streaming services (representing over 80% of industry revenues) are planning price increases — which could boost catalog values and royalty payouts.

    • Take Spotify ($SPOT), which charged $9.99/mo since its US launch in 2011, raised prices last year on all of its plans — and intends to do so again this year.

    • With the company paying ~70% of its revenues to music rights holders, even slight price hikes could mean big bucks for the music industry.

    It’s not all harmonious: Spotify’s 60% surge this year comes at a cost to artists and labels. In its latest earnings yesterday, the company reported record profits— but it took laying off a quarter of its staff, scaling back its podcast ambitions, and charging musicians for promotional features that used to be free to get there.

    Read: Music Companies Wage a War on AI-Generated Music


    AI Isn’t Waiting Around — And The Chance To Invest In This Company Certainly Isn’t

    All good things come to an end — and that includes the opportunity to invest in this AI company before their investment round closes this month.

    Using artificial intelligence, RAD AI has solved an age-old advertising pain point by pinpointing exactly what works and what doesn't in each campaign.

    Now they’re disrupting the $633B marketing technology industry by using AI to analyze billions of data points.

    • It’s so powerful that they’ve attracted customers like Skechers, Sweetgreen, MGM, and more — having grown their revenue by ~3x in 2023.

    • RAD AI has raised $27M from over 7K investors, including big shots from Google, Amazon, Meta- and the company is even backed by the Adobe Fund for Design.

    Invest in RAD AI


    🏥 UnitedHealth says Change Healthcare hack could cost $1.6B

    In the aftermath of a disruptive cyberattack affecting US pharmacies and hospitals, UnitedHealth Group ($UNH), the parent company of Change Healthcare, has confirmed that a hacker group stole sensitive medical data from a “substantial proportion of people in America.” Although UnitedHealth paid $22M to one of the hacking groups involved, the real cost will be much higher.

    • According to UnitedHealth, the attack, which involved the theft of 6TB of personally identifiable information as claimed by hacker group ALPHV, could cost the company $1.6B this year.

    • To address concerns among customers affected by the breach, the company has set up a website and support line, but direct communication with affected customers has not yet been initiated.

    Hacker blitz: 2023 marked the worst year for data breaches on record, but 2024’s hacks are already becoming a bigger deal in scale and sensitivity. The incident involving Change Healthcare could potentially rank among the worst hacks in American history. However, other major breaches — such as the recent attack on AT&T ($T), which compromised the social security numbers of 73M customers — indicate that 2024 might just surpass last year’s record-breaking cyberattacks.

    💊 The drug shortage is reaching critical levels

    If you’re having trouble filling your prescription meds, you aren’t alone. Right now, there are over 323 drugs in short supply, which is the highest it’s ever been. All drug classes are affected, from generic cancer drugs to commonly prescribed ADHD medication like Adderall. The frustrating part? Most of it is self-inflicted.

    • Overseas competition has suppressed generic drug prices — making it unprofitable for most domestic drugmakers to produce them.

    • As for Adderall, a confusing mix of rising demand, supply-chain issues, and DEA-imposed restrictions have led to a shortage since Oct. 2022.

    No quick fixes: The US urgently needs to shore up its drug manufacturing capacity — and both Biden and Trump are prioritizing domestic drug production to ensure supply chain resilience. In the meantime, the FTC is going after the “opaque middlemen” who contribute to these shortages. But the clock is ticking, and patients are feeling the strain, paying up to three times more on average for alternatives to hard-to-find drugs.

    Read: It’s not just patients; Lawmakers, insurers, and employers are fed up with high drug costs, too.


    🔗 PepsiCo / JetBlue

    CBDC, FedNow and the risks to your financial privacy. Global central banks are studying the implications of CBDCs (Central Bank Digital Currencies), including their impacts on the financial system, monetary policy, and financial stability. Navigate these turmoils and position for financial success by staying informed, diversifying your investments, and engaging in prudent financial planning. Achieve that with this Free Wealth Kit →*

    Markets & Economy

    NYSE considers 24-hour trading: Market players are pondering the idea of nonstop trading stocks — inspired partly by crypto’s 24/7 trading. A Steve Cohen-backed startup, 24 Exchange, is seeking SEC approval for round-the-clock trading. [Read]

    Bank of America ($BAC) bullish on Apple ($AAPL) for 2024: Setting a $225 price target for $AAPL, BofA is optimistic about the iPhone maker’s earnings next week, predicting strong margins and growth in its services segment. Morgan Stanley is more cautious, trimming their price target to $210 over worries about sales in China and weaker earnings. [Read]

    General Motors ($GM) shines in Q1, lifts 2024 outlook: Hearty truck sales led to a 7.6% revenue increase compared to last year, with net income rising by 26%. North American retail sales were particularly strong — prompting a ~$500M uptick in projected earnings for the year. [Read]

    Business & Wealth

    FTC blocks Coach-Michael Kors merger: Antitrust regulators fear such a fashion conglomerate could stifle competition for handbags and negatively impact employee compensation. Both companies plan to contest the decision in court. [Read]

    Over 70% of global workers endure extreme heat: Every year, ~18.9K workers succumb to excessive heat, while 22.9M suffer injuries. And there’s little relief in sight, as legislation in Texas and Florida prohibits local governments from instituting heat exposure protections like mandated breaks. [Read]

    Costco ($COST) customers struggle to sell gold bars: The retail giant made it easy to buy gold… but selling it is another story. Costco doesn’t buy back gold bars, and many refineries and local shops don’t offer market prices for gold. Selling gold isn’t as simple as selling stocks. [Read]

    *Thanks to our sponsors for keeping the newsletter free.


    Introducing: The News – Now with 399% more enjoyment!

    Our friends at The DONUT.co, deliver a 100% free newsletter keeping 150K+ daily readers informed and entertained.

    And they’re not your typical news…

    • ⚖️ Nonpartisan

    • 🪟 100% transparent

    • 😎 Prodigious wit

    • 🙅 No clickbait/sensationalism allowed

    In a nutshell, it’s news that lets you make up your own mind every morning in just 4 minutes – and a must-have if you wanna stay current without having a panic attack.🥳

    Start enjoying the news again for FREE with The DONUT.



    Investors Pull $2.2B From Cathie Wood's ARK ETF In 2024, More Than The Last Two Years Combined

    Cathie Wood’s ARK funds have hit an iceberg, but will it sink or sail on? Just four months into 2024, the investment firm's once-revered exchange-traded funds (ETFs) have seen $2.2B in outflows — with its flagship ARK Innovation ETF ($ARKK) hit the hardest. The recent downturn surpasses last year’s outflows, bringing total assets down to $11.1B — a stark drop from a high of $59B in 2021.

    • Back in 2020, ARK funds attracted $20B in deposits — but since then, the firm has seen a staggering $14.3B in investor money vanish, making it the biggest loss among asset managers over the past decade.

    • To start 2024, $ARKK shares slumped by 19% — primarily driven by Tesla ($TSLA), ARK’s largest holding, which plummeted ~45%, along with the absence of Nvidia ($NVDA).

    But can ARK weather the storm? ARK hopes to bounce back, especially if the Federal Reserve lowers interest rates. During its boom days, ARK’s funds rallied amid demand for growth stocks — and it hopes to capitalize again with the most growth-y stocks it can through its publicly-traded ARK Venture Fund ($ARKVX). Cathie Wood maintains a bullish stance, standing firm in her belief in ARK’s core investment themes and her confidence in Tesla’s future, for which she predicts a five-year price target of $2K, despite its current struggles.


    How was today's newsletter? Share your feedback…

    ❤️‍🔥 Issue was great. Now keep going.

    😐 Satisfied but do better.

    🥱 Is that all you got?

    Was this email forwarded to you? Subscribe here.

    Missed an issue? Catch up.

    Looking to advertise to 250K+ investors? Fill out this form

    Advertiser Disclaimer: This is a paid advertisement for RAD AI’s Regulation CF offering. Please read the offering circular at invest.radintel.ai.

    All content provided by The Average Joe is for informational and educational purposes only and should not be taken as trading or investment recommendations.

    Trending Posts